Summary & Overview
HCPCS G9205: Patient Starting Antiviral Treatment for Hepatitis C
HCPCS Level II code G9205 documents a patient who starts antiviral treatment for hepatitis C during the measurement period. This code is used to identify initiation of direct-acting antiviral therapy and to support quality measurement, reporting, and care coordination for hepatitis C treatment nationally. Tracking treatment starts is important for public health goals to reduce hepatitis C prevalence and to monitor adherence to clinical guidelines.
Payors referenced in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what G9205 represents, how it is applied in ambulatory and specialty settings, and the relevance for payer reporting and quality programs. The publication outlines benchmarking approaches, typical sites of service for treatment initiation, and the clinical context surrounding antiviral therapy starts. Data not available in the input for modifiers, associated taxonomies, ICD-10 diagnoses, and related codes are noted where applicable.
Billing Code Overview
HCPCS Level II code G9205 indicates a patient starting antiviral treatment for hepatitis C during the measurement period. This code documents initiation of antiviral therapy specifically for hepatitis C infection and is used to capture the start of a treatment episode for performance measurement and billing purposes.
-
Service type: Antiviral treatment initiation for hepatitis C
-
Typical site of service: Outpatient clinics, specialty hepatology or infectious disease practices, and other ambulatory care settings where antiviral therapy is prescribed and initiated
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 56-year-old patient with chronic hepatitis C virus (HCV) infection attends an outpatient hepatology clinic after confirmatory RNA testing. The clinician evaluates prior treatment history, genotype, liver fibrosis stage (noninvasive testing or transient elastography), concomitant medications, and potential drug–drug interactions. Following counseling about treatment goals and risks, the clinician prescribes an oral direct-acting antiviral (DAA) regimen and documents initiation of antiviral therapy during the measurement period. Typical workflow steps include medication reconciliation, baseline laboratory orders (HCV RNA quantitative, liver function tests, hepatitis B surface antigen, pregnancy test if applicable), insurance benefit verification and prior authorization if required, patient education on adherence and adverse effects, and scheduling follow-up HCV RNA testing to document virologic response. The typical site of service is an outpatient specialty clinic (hepatology or infectious disease) or primary care clinic experienced in HCV management. The patient scenario reflects initiation of a DAA regimen with documentation that treatment was started during the measurement period, which is the service represented by billing code G9205.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure or other service |